Darolutamide

Phase 3

BAYER (BAYRY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

BAYRYPhase 2$55.5B

Darolutamide Phase 2 Est. Readout

Darolutamide• High-Risk Localized Prostate Cancer100

Jun 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in High-Risk Localized Prostate Cancer

View Full Landscape

Drug Information

Target Indication

High-Risk Localized Prostate Cancer

Clinical Trial

NCT07450599

Last updated: 8/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

Cipro XR (Ciprofloxacin, BAYQ3939)Phase 3

Urinary Tract Infection

DabigatranPhase 3

Hematoma

bemdaneprocelPhase 3

Parkinsons Disease (PD)

D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3

Acute Coronary Syndrome

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts